We were delighted to speak to Christopher Ritchlin (University of Rochester, Henrietta, NY, USA) about the one year results from the DISCOVER-1 Phase 3 trial of guselkumab in active psoriatic arthritis (Clinical Trial Identification: NCT03162796). The abstract ‘Guselkumab, an IL-23 Inhibitor That Specifically Binds to the IL23p19-Subunit, for Active Psoriatic Arthritis: One Year Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Patients Who Were Biologic-Naïve or TNFα Inhibitor-Experienced.’ (ABSTRACT NUMBER: 1344) was presented at the virtual ACR Convergence 2020, 5-9 November 2020.
Questions
- What are the major unmet needs in the treatment of patients with active psoriatic arthritis? (0:16)
- What is guselkumab and what is its mechanism of action? (1:39)
- Could you tell us a little about the aims and design of the Phase 3 clinical study you are presenting? (2:56)
- What were the efficacy and safety findings of this study? (4:43)
- What are the implications of these findings for clinical practice? (5:31)
Disclosures: Consultant: Janssen, Abbvie, Amgen, UCB, Sanofi, Novartis, Lilly, Gilead
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of the ACR 2020 Annual Meeting (Virtual).
